Verastem Oncology Names Michael Bailey as CEO, Prices $250 Million Offering

Verastem Oncology named Michael Bailey as its next president and CEO and priced a stock offering expected to raise $250 million, while its shares climbed around 20% in premarket trading Wednesday, Oct. 14. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.